Track market-moving stories before they get noisy

ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (TSX: ALC) today announced it will report its financial results for the three and six months ended June 30, 2026 before market open on August 7, 2026. The Company's second quarter earnings release and full financial results will be available on the Company's website and on SEDAR. Algoma Central Corporation is a global provider of marine transportation, owning and operating dry and liquid bulk carriers that serve critical indus.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Alcon (ALC - Free Report) Headquartered in Geneva, Switzerland Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Founded in 1945, Alcon was first acquired by a Swiss subsidiary of Nestlé S.A. and operated as a wholly owned subsidiary of Nestlé until 2002. From March 20, 2002 until its 2011 merger into Novartis, Alcon was publicly listed and traded on the NYSE. In 2011, Novartis completed the acquisition of a full stake in Alcon.

ALC is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 19.69; value investors should take notice.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.00 to $3.50 per share. ALC boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALC should be on investors' short list.

RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustable intraocular lenses.

On a conference call, President and Chief Executive Officer Dr. Ron Kurtz said RxSight has been developing proprietary hybrid intraocular lens materials intended to support next-generation light-adjustable technology across premium lens categories. He said those efforts are being pursued through both the company’s standalone product pipeline and its collaboration with Alcon.

Get RxSight alerts:

“Our partnership with Alcon aims to leverage each company’s expertise to develop adjustable presbyopia-correcting IOLs that, for the first time, will enable doctors to refine visual outcomes noninvasively after surgery for patients who choose a PC IOL,” Kurtz said.

Preliminary Second-Quarter Results Chief Financial Officer Mark Wilterding said RxSight expects second-quarter total company revenue of approximately $32 million to $34 million. That includes an estimated $5 million to $7 million related to the RxSight-Alcon strategic collaboration agreement, subject to completion of quarter-end close procedures and the company’s accounting assessment.

Excluding revenue related to the agreement, preliminary total company sales were approximately $27 million in the second quarter, down 20% from the prior-year period. RxSight sold 24,917 Light Adjustable Lens, or LAL, units during the quarter, a 10% year-over-year decline.

The company sold 11 Light Delivery Devices, or LDDs, and placed one LDD rental unit during the period, bringing its installed base to 1,166 units. Wilterding said the company ended the quarter with cash, cash equivalents and short-term investments of approximately $209 million.

Guidance Revised for 2026 RxSight revised its full-year 2026 revenue outlook to a range of $140 million to $160 million. The company said that range reflects $110 million to $120 million in RxSight sales and $30 million to $40 million of revenue recognized from the Alcon collaboration agreement.

Wilterding said the updated sales guidance assumes the continuation of headwinds experienced in the second quarter. He added that collaboration agreement revenue remains subject to the terms and conditions described in the company’s SEC filing.

RxSight also raised its gross margin outlook, citing a favorable mix of LALs versus LDDs sold in the second quarter and an expectation that the trend will continue for the rest of 2026. The company now expects full-year gross margin of 73% to 75%, compared with previous guidance of 70% to 72%.

Operating expense guidance remained unchanged, with management continuing to expect expenses at the high end of the $150 million to $160 million range. Wilterding said that expectation includes accelerating investments in the LAL sales force and significant expenses related to the collaboration agreement.

Competitive Trialing and Consumer Sentiment Cited as Headwinds Kurtz said RxSight experienced near-term challenges in the second quarter after several quarters of relatively stable utilization trends. He attributed the retrenchment in part to “widespread competitive trialing activity associated with new product launches,” while noting that the company did not yet have second-quarter data from other premium IOLs.

He said trial programs can create “a significant short-term incentive” in an already strained practice environment, and management expects the heightened competitive environment to remain active through the end of the year.

Kurtz also cited pressure on consumer sentiment, which he said may have contributed to more deliberate patient decision-making and softer overall procedure activity. He noted that cataract surgery typically cannot be deferred indefinitely but said unusual declines in overall cataract volumes were observed in the first quarter, with patient confidence and the broader economic backdrop among potential factors.

To respond, RxSight plans to accelerate customer re-engagement efforts and make additional investments in its U.S. LAL sales force. Kurtz said the company aims to expand its depth of penetration within existing accounts.

Pipeline Updates Include Toric and Next-Generation LAL Products Kurtz said RxSight is working on next-generation LAL and LAL+ products, as well as LAL Toric, a lens designed to combine built-in Toric correction with postoperative refinement of residual sphere and cylinder. He said each product is intended to maintain high levels of visual quality and adjustability while improving workflow and reducing the number of required postoperative treatments.

In response to analyst questions, Kurtz said current use averages about one and a half or slightly more adjustments and about two “lock-in” treatments. He said the potential for a single lock-in treatment and built-in astigmatism correction could significantly reduce the number of postoperative treatments required.

Regarding the Alcon collaboration, Kurtz said the main benefit would be addressing residual refractive error, which he described as a leading reason for dissatisfaction after presbyopia-correcting IOLs. He said RxSight had not provided a specific timeline, but described the opportunity as within the company’s typical five-year planning period. He also declined to comment on the specific regulatory path for a combined technology, saying RxSight would collaborate with Alcon on that process.

Asked about whether an adjustable presbyopia-correcting IOL might overlap with RxSight’s existing offering, Kurtz said the company’s data show that most LAL patients come from monofocal or monofocal Toric lenses, with less than a quarter coming from presbyopia-correcting IOLs, including extended depth-of-focus and trifocal lenses. He said the Alcon collaboration would give RxSight access to an area in which it does not currently participate.

RxSight said its complete, unaudited second-quarter 2026 financial results are expected to be announced on Aug. 5, 2026.

About RxSight NASDAQ: RXSTRxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in RxSight Right Now?Before you consider RxSight, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.

While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

July 06, 2026 16:15 ET  | Source: RxSight, Inc.

Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologiesCollaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).

Under the collaboration, the companies will be innovating on their respective platforms – RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs – and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL.

“Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery,” said David J. Endicott, Chief Executive Officer of Alcon. “Together with RxSight’s technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery.”

“We are excited to work with Alcon to provide patients greater access to outcomes customized to their needs after surgery,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients.”

As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales.

About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding: potential payments that may be received by us in connection with the collaboration, including potential milestone payments and royalties; and RxSight’s and Alcon’s respective rights and obligations under the collaboration agreement, a description of which (including material terms and conditions) may be found in the Current Report on Form 8-K filed of even date herewith with the Securities and Exchange Commission (SEC). The forward-looking statements contained herein are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including, without limitation, uncertainty as to whether the anticipated benefits and opportunities of the proposed collaboration may be realized or make take longer to realize or may cost more than expected; risks of unexpected hurdles, costs or delays; challenges in technology transfer and manufacturing; challenges inherent in new product candidate development, including obtaining regulatory approvals; challenges associated with collaborating with third parties, including intellectual property, operational, financial and other risks; uncertainty of commercial success for new products; the ability of RxSight and Alcon to successfully execute their respective strategic plans; and other risks that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission (SEC) on May 6, 2026, and other documents that RxSight files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and RxSight assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Connect with us on
https://www.facebook.com/rxsight/
https://www.linkedin.com/company/rxsight/
https://www.instagram.com/rxsight/
http://www.youtube.com/@rxsight

Key Takeaways Alcon's new platforms and lenses are gaining adoption, while dry eye momentum supports future growth. Unity VCS, Unity CS and PanOptix Pro are driving equipment and implantables momentum for Alcon. ALC faces macro pressure, $33M in tariffs and intense competition across both operating segments. Alcon’s (ALC - Free Report) new platforms and lenses are gaining adoption. Dry eye momentum is likely to support growth in the upcoming quarters. However, adverse macroeconomic conditions and intense competition may harm the company’s operations.

In the past year, this Zacks Rank #3 (Hold) stock has dipped 25.1% compared with the industry’s 10.4% decline. The S&P 500 composite has risen 23.9% in the same time frame.

The renowned pharmaceutical and medical device manufacturer has a market capitalization of $32.77 billion. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%.

Let’s delve deeper.

Upsides for ALCBusiness Development Activities: Strategic asset additions have enabled Alcon to broaden its technology portfolio across both franchises, reinforcing a multi-year innovation pipeline that complements its internal R&D programs. In March 2026, Alcon and LENSAR agreed to terminate the previously announced merger agreement, which removes a near-term integration item and keeps capital available for other bolt-on opportunities.

In 2025, the company acquired a majority interest in Aurion Biotech to advance AURN001, a corneal cell therapy candidate that targets a large transplant market constrained by donor availability. Alcon also completed the acquisition of LumiThera and its Valeda photobiomodulation device for early and intermediate dry AMD. 

New Products to Drive Growth: Unity VCS and Unity CS are at the center of the current equipment cycle, with management highlighting continued momentum in the first quarter of 2026 as installations expand and surgeon feedback emphasizes workflow integration. In implantables, PanOptix Pro is being rolled out internationally following U.S. adoption. 

Alcon reported share gains in U.S. AT-IOLs and is preparing to launch an upgraded Vivity lens in early 2027. TruPlus adds a monofocal plus option with toric availability at launch, supporting broader coverage of astigmatism correction. Alcon also continues to scale Tryptyr and Systane in dry eye and broaden its contact lens lineup with TOTAL30 and PRECISION7, including a multifocal toric extension of TOTAL30 introduced in early 2026. 

Image Source: Zacks Investment Research

Downsides for ALCPersistent Macroeconomic Pressure: Alcon remains exposed to geopolitical and trade volatility that can disrupt supply chains and raise input costs, particularly as tariffs continue to evolve. In the first quarter of 2026, incremental tariffs in the United States and China totaled $33 million, and management cited a 120 basis points drag on core gross margin. 

Tough Competitive Landscape: Competition remains intense across both segments and is showing up most clearly where Alcon is defending share outside the United States and managing mix transitions. The category also remains competitive as newer entrants target value tiers and the market continues shifting toward daily lenses and advanced materials. These dynamics increase reliance on newer platforms to sustain growth, requiring continued investment in commercialization and physician education to maintain pricing power and market positioning over time.

ALC Stock Estimate Trend The Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $3.48 in the past 30 days.

The Zacks Consensus Estimate for 2026 revenues is pegged at $11.06 billion, suggesting a 7.2% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . 

Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Alcon (ALC - Free Report) Headquartered in Geneva, Switzerland Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Founded in 1945, Alcon was first acquired by a Swiss subsidiary of Nestlé S.A. and operated as a wholly owned subsidiary of Nestlé until 2002. From March 20, 2002 until its 2011 merger into Novartis, Alcon was publicly listed and traded on the NYSE. In 2011, Novartis completed the acquisition of a full stake in Alcon.

ALC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 18.59; value investors should take notice.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.02 to $3.48 per share. ALC boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALC should be on investors' short list.

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2026) - Mexican Gold Mining Corp. (TSXV: MEX) ("Mexican Gold" or the "Company") and Alcon Silver Corp. ("Alcon") announce that, in connection with the previously announced arrangement agreement dated April 8, 2026 between the Company and Alcon (the "Arrangement Agreement"), the Company intends to complete a non-brokered private placement of up to 11,250,000 subscription receipts of the Company (the "Subscription Receipts") at a price of $0.20 per Subscription Receipt, for aggregate gross proceeds of up to $2,250,000 (the "Offering"). The Offering constitutes a concurrent financing to the Arrangement (as defined below) and is subject to acceptance of the TSX Venture Exchange (the "TSXV").

On April 8, 2026, Mexican Gold and Alcon entered into the Arrangement Agreement, pursuant to which Mexican Gold will acquire all of the issued and outstanding common shares of Alcon (the "Alcon Shares") in exchange for newly issued common shares in the capital of Mexican Gold (the "Consideration Shares") at an exchange ratio of 1.0 post-Consolidation Mexican Gold common share for each Alcon Share, by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). In connection with the Arrangement, Mexican Gold will complete a consolidation of its outstanding common shares on a 1.6667-to-1 basis (the "Consolidation") and a change of its corporate name to Platauro Metals Corp. (the "Name Change"). The Supreme Court of British Columbia has granted an interim order in respect of the Arrangement authorizing the calling and holding of a meeting of Alcon shareholders to approve the Arrangement (the "Meeting"). The Meeting is scheduled to be held on July 3, 2026, and shareholders of Alcon have now been mailed proxy materials as well as an information circular describing the Arrangement. See the Company and Alcon's news release dated April 8, 2026 for further details regarding the Arrangement.

In connection with the Arrangement, Mexican Gold and Alcon have entered into an interim loan agreement dated June 12, 2026 (the "Interim Loan Agreement"), pursuant to which Mexican Gold has agreed to advance to Alcon an unsecured, non-interest bearing loan in the principal amount of $250,000 (the "Interim Loan"). The proceeds of the Interim Loan will be used by Alcon for general corporate purposes, working capital requirements, regulatory compliance, professional fees, property maintenance costs and other ordinary-course expenditures pending completion of the Arrangement. Upon completion of the Arrangement, the Interim Loan will be automatically satisfied, discharged, cancelled and extinguished without any further action by either party. If the Arrangement is not completed on or before August 31, 2026 (or such later date as the parties may agree), the Interim Loan will become a conventional third-party loan bearing interest at 12% per annum and will be repayable upon demand by Mexican Gold. As a result of the Offering and the Interim Loan, Alcon will discontinue the marketing of the remaining $117,650 of its convertible debenture offering detailed in its management information circular dated May 26, 2026, which was mailed to Alcon security holders on June 5, 2026. The terms of the convertible debentures were disclosed in the news release dated April 8, 2026.

As of the date of the Arrangement Agreement, Mexican Gold had 41,216,639 common shares outstanding (on a pre-Consolidation basis, excluding shares issuable under the Offering). Upon completion of the Arrangement, the Consolidation and the Offering (assuming the maximum Offering), the Company expects to have approximately 76,434,426 common shares outstanding on a post-Consolidation basis.

Details of the Offering

Each Subscription Receipt will automatically entitle the holder, upon closing of the Arrangement, without further action by the holder and without payment of additional consideration, to receive one post-Consolidation and post-Name Change common share of the Company (a "New Issue Share") and one-half of one post-Consolidation and post-Name Change common share purchase warrant.

Each whole common share purchase warrant issuable upon conversion of the Subscription Receipts (a "New Issue Warrant") will entitle the holder to acquire one New Issue Share at an exercise price of $0.30 per New Issue Share for a period of thirty (30) months following the closing date of the Arrangement

The gross proceeds from the Offering (the "Subscription Proceeds") will be held in escrow pending satisfaction or waiver of certain escrow release conditions to be set out in the subscription agreements for the Subscription Receipts (the "Escrow Release Conditions"). The Escrow Release Conditions must be satisfied or waived on or before August 31, 2026, unless extended by agreement of the applicable parties for up to an additional 60 business days if the required regulatory approvals have not been obtained by such date (the "Escrow Release Deadline").

The Escrow Release Conditions include, among other things: receipt of acceptance from the TSXV for the Arrangement, the Consolidation, the Name Change, and the Offering; approval of the Arrangement by the shareholders of Alcon; receipt of an order of the Supreme Court of British Columbia approving the plan of arrangement; and the concurrent closing of the Arrangement.

If the Escrow Release Conditions are not satisfied or waived by the Escrow Release Deadline, the Subscription Proceeds will be returned to subscribers without deduction.

Following release from escrow, the net Subscription Proceeds will be used for exploration of the Princesa project, exploration of the Rowdy claim at Tatatila, legal fees associated with the Las Minas claims dispute, and for general corporate and working capital purposes.

In connection with the Offering, the Company may pay finder's fees in cash or securities, or a combination of both, as permitted by the policies of TSXV and applicable securities legislation. All securities issued pursuant to the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities legislation.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or in any other jurisdiction, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold in the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to an exemption therefrom.

Additional Information

Copies of the Arrangement Agreement and the Interim Loan Agreement have been filed on SEDAR+ and are available for viewing under the Company's profile at www.sedarplus.ca.

About Mexican Gold Mining Corp.

Mexican Gold is a Canadian-based mineral exploration and development company committed to building long term value through ongoing discoveries and strategic acquisitions of prospective precious metals and copper projects in the Americas. Mexican Gold is exploring and advancing the Las Minas Project, which is located in the core of the Las Minas mining district in Veracruz State, Mexico, and host to one of the newest, under-explored skarn systems known in Mexico. Mexican Gold recently expanded its land package by acquiring the adjacent Tatatila claims from Chesapeake Gold.

About Alcon Silver Corp.

Alcon Silver Corp is a private silver explorer focused on advancing its 100% owned Princesa Silver-Polymetallic Project in the Puno-Cusco Mining District, Peru, and its Star Silver-Polymetallic Project in the historic Beaver Mining District south of Milford, Utah.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information in this news release includes, but is not limited to, statements regarding: the proposed Offering, including the size, pricing, terms and expected completion thereof; the intended use of proceeds of the Offering; the anticipated release of the Subscription Proceeds from escrow; the satisfaction or waiver of the Escrow Release Conditions; the expected terms of the New Issue Shares and New Issue Warrants issuable upon conversion of the Subscription Receipts; the anticipated completion of the Arrangement; the completion of the Consolidation and the Name Change; the receipt of all required shareholder, court, regulatory and stock exchange approvals, including acceptance of the TSX Venture Exchange; the expected timing for completion of the Offering, the Arrangement and related transactions; the terms, use of proceeds and treatment of the Interim Loan upon completion of the Arrangement; and the anticipated business, plans and prospects of the Company following completion of the Arrangement.

Forward-looking information is based on assumptions that management considers reasonable as of the date of this news release, including assumptions regarding: the ability of Mexican Gold and Alcon to obtain all required approvals on acceptable terms and within expected timelines; the ability of the parties to satisfy or waive the conditions to completion of the Offering and the Arrangement; investor participation in the Offering; the absence of material adverse changes affecting Mexican Gold, Alcon or their respective businesses, assets or capital markets generally; the satisfaction and discharge of the Interim Loan upon completion of the Arrangement; and the ability of the Company to use the net proceeds of the Offering as currently contemplated.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: the risk that the Offering may not be completed on the terms currently proposed or at all; the risk that the Subscription Proceeds may not be released from escrow; the risk that the Escrow Release Conditions may not be satisfied or waived by the Escrow Release Deadline; the risk that required shareholder, court, regulatory or stock exchange approvals may not be obtained; the risk that the Arrangement, the Consolidation or the Name Change may not be completed on the terms currently proposed or at all; the risk that the Interim Loan may not be satisfied and discharged upon completion of the Arrangement or may become repayable if the Arrangement is not completed; risks associated with changes in market conditions, investor demand, commodity prices and securities markets; risks inherent in the mineral exploration industry; and the risk factors described in the Company's public disclosure documents available under the Company's profile on SEDAR+ at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained in this news release is made as of the date hereof, and the Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301344

Source: Mexican Gold Mining Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of Phreesia, Inc. (NYSE:PHR). In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Phreesia stock on March 5th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of ENN Energy (OTCMKTS:XNGSY) on 3/24/2026. Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 3/24/2026. Purchased $1,001 – $15,000 in shares of Fabrinet (NYSE:FN) on 3/24/2026. Sold $1,001 – $15,000 in shares of Intapp (NASDAQ:INTA) on 3/12/2026. Sold $1,001 – $15,000 in shares of Alcon (NYSE:ALC) on 3/12/2026. Sold $1,001 – $15,000 in shares of La-Z-Boy (NYSE:LZB) on 3/12/2026. Sold $1,001 – $15,000 in shares of HDFC Bank (NYSE:HDB) on 3/12/2026. Sold $1,001 – $15,000 in shares of Infineon Technologies (OTCMKTS:IFNNY) on 3/12/2026. Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/10/2026. Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 3/6/2026. Phreesia Stock Down 7.7% Shares of PHR stock opened at $8.08 on Friday. The stock has a market cap of $490.94 million, a P/E ratio of 269.33 and a beta of 0.86. Phreesia, Inc. has a 52 week low of $7.77 and a 52 week high of $32.76. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The company’s fifty day simple moving average is $11.43 and its two-hundred day simple moving average is $16.92.

Phreesia (NYSE:PHR – Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). The company had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.11) EPS. Analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling In related news, General Counsel Allison C. Hoffman sold 6,176 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $11.97, for a total value of $73,926.72. Following the sale, the general counsel directly owned 163,485 shares of the company’s stock, valued at $1,956,915.45. This represents a 3.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Evan Roberts sold 6,268 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $102,544.48. Following the completion of the sale, the insider directly owned 826,554 shares in the company, valued at $13,522,423.44. This trade represents a 0.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 40,367 shares of company stock worth $613,251 over the last three months. 5.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes Several analysts have commented on PHR shares. Canaccord Genuity Group decreased their price target on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a research note on Wednesday, January 28th. Zacks Research cut shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wells Fargo & Company decreased their target price on shares of Phreesia from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, March 26th. Finally, Needham & Company LLC decreased their target price on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Phreesia currently has an average rating of “Moderate Buy” and an average target price of $22.00.

Read Our Latest Research Report on Phreesia

Institutional Trading of Phreesia A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. Royal Bank of Canada raised its position in Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after purchasing an additional 16,309 shares during the period. AQR Capital Management LLC raised its position in Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after purchasing an additional 2,158 shares during the period. NewEdge Advisors LLC raised its position in Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after purchasing an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Phreesia by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after purchasing an additional 2,402 shares during the period. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Representative Gottheimer Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Phreesia Company Profile (Get Free Report)

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

See Also Five stocks we like better than Phreesia Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Apr 10th, 2026

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of Infineon Technologies AG (OTCMKTS:IFNNY). In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Infineon Technologies stock on March 12th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of ENN Energy (OTCMKTS:XNGSY) on 3/24/2026. Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 3/24/2026. Purchased $1,001 – $15,000 in shares of Fabrinet (NYSE:FN) on 3/24/2026. Sold $1,001 – $15,000 in shares of Intapp (NASDAQ:INTA) on 3/12/2026. Sold $1,001 – $15,000 in shares of Alcon (NYSE:ALC) on 3/12/2026. Sold $1,001 – $15,000 in shares of La-Z-Boy (NYSE:LZB) on 3/12/2026. Sold $1,001 – $15,000 in shares of HDFC Bank (NYSE:HDB) on 3/12/2026. Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/10/2026. Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 3/6/2026. Sold $1,001 – $15,000 in shares of Columbia Banking System (NASDAQ:COLB) on 3/5/2026. Infineon Technologies Price Performance Shares of OTCMKTS IFNNY opened at $50.05 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.94 and a current ratio of 1.72. The company has a market cap of $61.49 billion, a PE ratio of 53.82, a P/E/G ratio of 0.94 and a beta of 1.83. The business has a 50-day simple moving average of $48.58 and a two-hundred day simple moving average of $44.40. Infineon Technologies AG has a fifty-two week low of $28.26 and a fifty-two week high of $56.19.

Infineon Technologies (OTCMKTS:IFNNY – Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The technology company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.05. Infineon Technologies had a return on equity of 11.12% and a net margin of 7.51%.The business had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $3.65 billion. As a group, equities analysts expect that Infineon Technologies AG will post 1.61 EPS for the current fiscal year.

Analysts Set New Price Targets A number of equities research analysts recently commented on IFNNY shares. JPMorgan Chase & Co. raised Infineon Technologies from a “neutral” rating to an “overweight” rating in a report on Friday, March 20th. Zacks Research downgraded Infineon Technologies from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 11th. Wall Street Zen raised Infineon Technologies from a “hold” rating to a “buy” rating in a report on Thursday, February 12th. Finally, UBS Group downgraded Infineon Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

View Our Latest Report on IFNNY

About Representative Gottheimer Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Infineon Technologies Company Profile (Get Free Report)

Infineon Technologies AG (OTCMKTS:IFNNY) is a global semiconductor manufacturer that develops, manufactures and markets a broad range of semiconductor and system solutions. The company’s product portfolio includes power semiconductors and modules, microcontrollers and system-on-chip (SoC) solutions, analog and mixed-signal components, sensors and security controllers. Infineon’s technologies are used to enable energy-efficient power conversion, electrification, connectivity and secure data processing across multiple end markets.

Infineon was formed as a spin-off from Siemens AG in 1999 and is headquartered near Munich in Neubiberg, Germany.

Featured Stories Five stocks we like better than Infineon Technologies Receive News & Ratings for Infineon Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infineon Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMorgan Stanley Increases Sportradar Group (NASDAQ:SRAD) Price Target to $25.00

NEXT HEADLINE »Rep. Gilbert Ray Cisneros, Jr. Buys Fidelity National Information Services, Inc. (NYSE:FIS) Shares

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Alcon (ALC - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Alcon is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alcon is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ALC's full-year earnings has moved 3.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, ALC has moved about 1.2% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5.8% on a year-to-date basis. This shows that Alcon is outperforming its peers so far this year.

Another Medical stock, which has outperformed the sector so far this year, is Brainsway Ltd. Sponsored ADR (BWAY - Free Report) . The stock has returned 51.3% year-to-date.

In Brainsway Ltd. Sponsored ADR's case, the consensus EPS estimate for the current year increased 5.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).

To break things down more, Alcon belongs to the Medical - Instruments industry, a group that includes 77 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 12.9% so far this year, so ALC is performing better in this area.

On the other hand, Brainsway Ltd. Sponsored ADR belongs to the Medical - Products industry. This 78-stock industry is currently ranked #157. The industry has moved -13.4% year to date.

Going forward, investors interested in Medical stocks should continue to pay close attention to Alcon and Brainsway Ltd. Sponsored ADR as they could maintain their solid performance.

GENEVA--(BUSINESS WIRE)--Regulatory News:

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2026 Annual General Meeting (“AGM”).

A total of 283,222,421 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 11,328,896.84, were represented at today's AGM.

Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood for re-election, namely Lynn Bleil, Arthur Cummings, Deborah Di Sanzo, David Endicott, Thomas Glanzmann, D. Keith Grossman, Karen May, Ines Pöschel and Dieter Spälti, for a term of office of one year. Shareholders also elected R. Scott Herren to the Board.

In addition, shareholders re-elected Thomas Glanzmann, Karen May and Ines Pöschel to form the Compensation Committee for a period of one year.

Discharge was granted to the members of the Board of Directors and the members of the Executive Committee for the 2025 financial year.

In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2027 Annual General Meeting, and the Executive Committee for the 2027 financial year.

Shareholders also accepted the 2025 Report on Non-Financial Matters and the 2025 Compensation Report in separate, non-binding, consultative votes.

Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2025.

Shareholders also approved that a gross dividend of CHF 0.28 per dividend-bearing share be declared, and that, after appropriation of the dividend, the remaining amount of available earnings be carried forward.

PricewaterhouseCoopers SA, Geneva, was re-elected as statutory auditors for the 2026 financial year. Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative for a term of one year extending until the 2027 AGM.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Connect with us on
Facebook
LinkedIn

More News From Alcon Inc. Swiss

GENEVA--(BUSINESS WIRE)--Regulatory News:

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2026. For the first quarter of 2026, sales were $2.7 billion, up 10% on a reported basis and up 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.39 and core diluted earnings per share2 of $0.85 in the first quarter of 2026.

“2026 is off to a solid start, driven by strong performance from our new product launches, including Unity VCS and CS, PanOptix Pro, Tryptyr and Precision7. Combined with the resilience of our balanced portfolio, we are well positioned to navigate market variability and maintain consistent performance,” said David J. Endicott, Alcon's Chief Executive Officer. “Our innovation remains a key growth engine, delivering differentiated technologies that reinforce our leadership in eye care and support sustained revenue growth and margin expansion.”

First-quarter 2026 key figures

Three months ended March 31

2026

2025

Net sales ($ millions)

2,685

2,451

Operating margin (%)

10.9%

19.1%

Diluted earnings per share ($)

0.39

0.70

Core results (non-IFRS measure)2

Core operating margin (%)

21.2%

20.8%

Core diluted earnings per share ($)

0.85

0.73

Cash flows ($ millions)

Net cash flows from operating activities

418

384

Free cash flow (non-IFRS measure)3

279

278

First-quarter 2026 results

Reported net sales for the first quarter of 2026 were $2.7 billion, up 10% versus the first quarter of 2025. Excluding favorable currency impacts of 4%, sales were up 6% on a constant currency basis.

The following table highlights net sales by segment for the first quarter of 2026:

Three months ended
March 31

Change %

($ millions unless indicated otherwise)

2026

2025

$

cc1
(non-IFRS
measure)

Surgical

Implantables

438

420

4

1

Consumables

769

712

8

4

Equipment/other

253

199

27

23

Total Surgical

1,460

1,331

10

6

Vision Care

Contact lenses

738

688

7

4

Ocular health

487

432

13

10

Total Vision Care

1,225

1,120

9

6

Net sales

2,685

2,451

10

6

Net sales by segment

Surgical

Surgical net sales, which include implantables, consumables and equipment/other, were $1.5 billion, an increase of 10% on a reported basis and 6% on a constant currency basis versus the first quarter of 2025.

Implantables net sales were $438 million, an increase of 4%. Excluding favorable currency impacts of 3%, Implantables net sales increased 1% constant currency. This growth reflects strong performance by PanOptix Pro, continued competitive pressures in international markets and lower sales in surgical glaucoma. Consumables net sales were $769 million, an increase of 8%. Excluding favorable currency impacts of 4%, Consumables net sales increased 4% constant currency, reflecting soft cataract market conditions and price increases. Equipment/other net sales were $253 million, an increase of 27%. Excluding favorable currency impacts of 4%, Equipment/other net sales increased 23% constant currency. This growth was led by recent equipment launches, including the Unity platform. Vision Care

Vision Care net sales, which include contact lenses and ocular health, were $1.2 billion, an increase of 9% on a reported basis and 6% on a constant currency basis versus the first quarter of 2025.

Contact lenses net sales were $738 million, an increase of 7%. Excluding favorable currency impacts of 3%, Contact lenses net sales increased 4% constant currency. This growth reflects product innovation and price increases, partially offset by declines in legacy products. Ocular health net sales were $487 million, an increase of 13%. Excluding favorable currency impacts of 3%, Ocular health net sales increased 10% constant currency. Growth was led by our portfolio of dry eye products, including Tryptyr and Systane. Operating income

Operating income was $292 million (-38%, -42% cc), compared to $468 million in the prior year period. Operating margin decreased 8.2 percentage points. The prior year period included gains on fair value remeasurements of investments in associated companies. The current year period included costs associated with efficiency initiatives, impairment charges related to an intangible asset, incremental tariffs, sales and marketing behind new product launches and increased research and development ("R&D"), partially offset by improved operating leverage from higher sales and manufacturing efficiencies. Excluding a positive 0.5 percentage point impact from currency, operating margin decreased 8.7 percentage points on a constant currency basis.

Adjustments to arrive at core operating income in the current year period were $277 million, mainly due to $129 million of amortization, $88 million of costs associated with efficiency initiatives, $38 million of impairment charges related to an intangible asset and $21 million of acquisition and integration related items. Adjustments to arrive at core operating income in the prior year period were $43 million, mainly due to $172 million of amortization and $13 million of acquisition and integration related items, partially offset by gains of $142 million on fair value remeasurements of investments in associated companies.

Core operating income was $569 million (+11%, +6% cc), compared to $511 million in the prior year period. Core operating margin increased 0.4 percentage points as the current year period included improved operating leverage from higher sales and manufacturing efficiencies, partially offset by incremental tariffs, sales and marketing behind new product launches and increased R&D. Excluding a positive 0.4 percentage point impact from currency, core operating margin was in line with the prior year period on a constant currency basis.

Taxes

Reported tax expense was $51 million, compared to $64 million in the prior year period, and the average reported tax rate was 21.3%, compared to 15.5% in the prior year period. The prior year period included a non-taxable gain on the fair value remeasurement of an investment in an associated company.

Core tax expense was $102 million, compared to $97 million in the prior year period, and the average core tax rate was 19.7%, compared to 21.0% in the prior year period. The decrease in average core tax rate is primarily driven by a more favorable mix of pre-tax income/(loss) across geographical tax jurisdictions and the tax effect of an increase of inventory in certain international markets, partially offset by discrete tax expenses in the current year period.

Diluted earnings per share

Diluted earnings per share of $0.39 decreased 44%, or 50% on a constant currency basis, versus the prior year period. The prior year period included gains of $142 million on fair value remeasurements of investments in associated companies. Core diluted earnings per share of $0.85 increased 16%, or 10% on a constant currency basis, versus the prior year period.

Cash flow highlights

Net cash flows from operating activities amounted to $418 million for the first three months of 2026, compared to $384 million in the prior year period. Free cash flow was $279 million for the first three months of 2026, compared to $278 million in the prior year period.

Capital allocation

Dividend

On April 30, 2026, at the Company's Annual General Meeting, shareholders approved a dividend of CHF 0.28 per share, which is expected to be paid on or around May 7, 2026. The total dividend payments will amount to a maximum of $177 million using the CHF/USD exchange rate as of April 30, 2026.

Share repurchase authorization

On May 5, 2026, the Board authorized the repurchase of up to $1.5 billion of the Company’s common shares, par value of CHF 0.04 per share, on a second trading line with the SIX Swiss Exchange. The shares to be acquired under this share buyback program will be cancelled as a return of capital to shareholders.

Alcon expects to fund the program through cash generated from operations. The program is subject to customary safe harbor conditions and authorization of the Swiss Takeover Board. The timing and total amount of share repurchases and cancellations will depend upon a variety of factors. The program is expected to be completed over a three-year period, but may be suspended or discontinued at any time.

Further information (including official publications in English, German and French) will be available as of May 6, 2026 at https://investor.alcon.com/stock-information/share-repurchase-history/default.aspx.

2026 outlook

The Company updated its 2026 outlook as per the table below.

2026 outlook4

as of February

as of May

Comments

Net sales growth vs. prior year (cc)1

(non-IFRS measure)

+5% to +7%

+5% to +7%

Maintained

Core operating margin2 change vs. prior year (cc)1

(non-IFRS measure)

+70 to +170 bps

+70 to +170 bps

Maintained

Core diluted EPS2 growth vs. prior year (cc)1

(non-IFRS measure)

+9% to +12%

+10% to +13%

Updated

This outlook assumes the following:

Aggregated markets grow approximately 3% to 4%. A full-year tariff impact, net of mitigating actions, of approximately $100 to $150 million, which is expected to pressure cost of net sales. This reduction in tariff expense versus Alcon's February outlook is expected to be reinvested in the business. This estimate excludes any potential refunds. Exchange rates as of the end of April 2026 prevail through year-end, which remain in line with the Company's February outlook. Non-operating expense5 for FY 2026 is expected to be between $200 and $220 million. The core effective tax rate6 for FY 2026 is expected to be approximately 20%. Capital expenditures are expected to be mid-single digits as a percentage of sales. Approximately 492 million weighted-averaged diluted shares.7 Webcast and Conference Call Instructions

The Company will host a conference call on May 6, 2026 at 8:00 a.m. Eastern Time / 2:00 p.m. Central European Time to discuss its first-quarter 2026 earnings results. The webcast can be accessed online through Alcon's Investor Relations website, i.e. investor.alcon.com. Listeners should log on approximately 10 minutes in advance. A replay will be available online within 24 hours after the event. To listen the Company's conference call, click on the link:

https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2026/Alcons-First-Quarter-2026-Earnings-Call-2026-HSeoMI-KHy/default.aspx

The Company's first-quarter 2026 press release, interim financial report and supplemental presentation materials can be found online through Alcon's Investor Relations website, or by clicking on the link:

https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2026/Alcons-First-Quarter-2026-Earnings-Call-2026-HSeoMI-KHy/default.aspx

Cautionary Note Regarding Forward-Looking Statements

This press release contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our 2026 outlook, liquidity, revenue, revenue growth, gross margin, operating margin, core operating margin, core operating margin growth, effective tax rate, foreign currency exchange movements, tariff impact, nonoperating expenses, earnings per share, earnings per share growth, operating cash flow, free cash flow, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches and technology failures that could disrupt operations; our ability to effectively manage the risks associated with transformational information technology changes such as the ethical use of artificial intelligence and disruptive technologies and the migration to cloud-based platforms; compliance with data privacy, identity protection and information security laws, particularly with the increased use of artificial intelligence; the impact of a disruption in our global supply chain, including the effect of tariffs, or important facilities, particularly when we single-source or rely on limited sources of supply; our reliance on outsourcing key business functions; the increasingly challenging economic, political and legal environment in China; global and regional economic, financial, monetary, legal, tax, political and social change; our ability to comply with anti-corruption, anti-bribery, export control, trade sanction, or similar laws; our ability to attract and retain qualified personnel; our ability to manage the risks associated with operating as a third party contract manufacturer; our success in completing strategic acquisitions, including equity investments in early-stage companies, on favorable terms or at all, and in integrating acquired businesses; the success of our research and development efforts, including our ability to innovate to compete effectively; our ability to manage the rapid evolution and adoption of artificial intelligence; terrorism, war and similar events; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to comply with all laws to which we may be subject; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; the effect of product recalls or voluntary market withdrawals; our ability to manage social impact and sustainability matters; our ability to properly educate and train healthcare providers on our products; our ability to protect our intellectual property; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets, and the adequacy of our financial reporting, accounting practices and internal controls; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; the effect of maintaining or losing our foreign private issuer status under US securities laws; and the ability to enforce US judgments against Swiss corporations.

Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. We also undertake no obligation to update the 2026 outlook as circumstances evolve.

Intellectual Property

This report may contain references to our proprietary intellectual property. All product names appearing in italics or ALL CAPS are trademarks owned by or licensed to Alcon Inc. Product names identified by a "®" or a "™" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners.

Non-IFRS measures as defined by the Company

Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currency, EBITDA, free cash flow and net (debt)/liquidity.

Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These supplemental non-IFRS measures are presented solely to permit investors to more fully understand how Alcon management assesses underlying performance. These supplemental non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures.

Core results

Alcon core results, including core operating income and core net income, exclude all amortization and impairment charges of intangible assets, excluding software, product discontinuation charges, net gains and losses on fund investments and equity securities valued at fair value through profit and loss ("FVPL"), fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, fair value remeasurements of investments in associated companies and certain acquisition related items. The following items that exceed a threshold of $10 million, are not operating expenses necessary to the operation of the business and have costs that will vary over periods are also excluded from core results: integration and divestment related income and expenses, divestment gains and losses, restructuring charges/releases and related items, legal related items, gains/losses on early extinguishment of debt or debt modifications, past service costs for post-employment benefit plans, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a $10 million threshold.

Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for certain items such as legal settlements in certain jurisdictions.

Alcon believes that investor understanding of its performance is enhanced by disclosing core measures of performance because, since they exclude items that can vary significantly from period to period, the core measures enable a helpful comparison of business performance across periods. For this same reason, Alcon uses these core measures in addition to IFRS and other measures as important factors in assessing its performance.

A limitation of the core measures is that they provide a view of Alcon operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets and restructurings.

Constant currency

Changes in the relative values of non-US currencies to the US dollar can affect Alcon's financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about changes in our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects.

Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the Consolidated Income Statement excluding:

the impact of translating the income statements of consolidated entities from their non-US dollar functional currencies to the US dollar; and the impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency. Alcon calculates constant currency measures by translating the current year's foreign currency values for sales and other income statement items into US dollars, using the average exchange rates from the historical comparative period and comparing them to the values from the historical comparative period in US dollars.

EBITDA

Alcon defines earnings before interest, tax, depreciation and amortization ("EBITDA") as net income excluding income taxes, depreciation of property, plant and equipment (including any related impairment charges), depreciation of right-of-use assets, amortization of intangible assets (including any related impairment charges), interest expense and other financial income and expense. Alcon management primarily uses EBITDA together with net (debt)/liquidity to monitor leverage associated with financial debts.

Free cash flow

Alcon defines free cash flow as net cash flows from operating activities less cash flow associated with the purchase or sale of property, plant and equipment. Free cash flow is presented as additional information because Alcon management believes it is a useful supplemental indicator of Alcon's ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS.

Net (debt)/liquidity

Alcon defines net (debt)/liquidity as current and non-current financial debt less cash and cash equivalents, current investments, including time deposits, and derivative financial instruments. Net (debt)/liquidity is presented as additional information because management believes it is a useful supplemental indicator of Alcon's ability to pay dividends, to meet financial commitments and to invest in new strategic opportunities, including strengthening its balance sheet.

Growth rate and margin calculations

For ease of understanding, Alcon uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared to the prior year is shown as a positive growth.

Gross margins, core gross margins, operating income margins and core operating income margins are calculated based upon net sales unless otherwise noted.

Reconciliation of guidance for forward-looking non-IFRS measures

The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable efforts, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. These items are uncertain, depend on many factors and could have a material impact on our IFRS results for the guidance period.

Financial tables

Net sales by region

Three months ended March 31

($ millions unless indicated otherwise)

2026

2025

United States

1,228

46

%

1,137

46

%

International

1,457

54

%

1,314

54

%

Net sales

2,685

100

%

2,451

100

%

Consolidated Income Statement (unaudited)

Three months ended March 31

($ millions except earnings per share)

2026

2025

Net sales

2,685

2,451

Other revenues

21

22

Net sales and other revenues

2,706

2,473

Cost of net sales

(1,163

)

(1,071

)

Cost of other revenues

(18

)

(19

)

Gross profit

1,525

1,383

Selling, general & administration

(882

)

(813

)

Research & development

(245

)

(222

)

Other income

11

149

Other expense

(117

)

(29

)

Operating income

292

468

Interest expense

(52

)

(49

)

Other financial income & expense

2

9

Share of (loss) from associated companies

(2

)

(14

)

Income before taxes

240

414

Taxes

(51

)

(64

)

Net income

189

350

Net income attributable to:

Shareholders of Alcon Inc.

189

350

Non-controlling interests

—

—

Earnings per share ($)(1)

Basic

0.39

0.71

Diluted

0.39

0.70

Weighted average number of shares outstanding (millions)

Basic

487.2

495.1

Diluted

490.2

498.0

Segment contribution

Three months ended March 31

Change %

($ millions unless indicated otherwise)

2026

2025

$

cc(1)
(non-IFRS
measure)

Surgical segment contribution

367

336

9

4

As % of net sales

25.1

25.2

Vision Care segment contribution

294

281

5

2

As % of net sales

24.0

25.1

Not allocated to segments

(369

)

(149

)

(148

)

(145

)

Operating income

292

468

(38

)

(42

)

Core adjustments (non-IFRS measure)(1)

277

43

Core operating income (non-IFRS measure)(1)

569

511

11

6

Operating income

Three months ended March 31

Change %

($ millions unless indicated otherwise)

2026

2025

$

cc(1)
(non-IFRS
measure)

Cost of net sales

(1,163

)

(1,071

)

(9

)

(6

)

Gross profit

1,525

1,383

10

6

Gross margin (%)

56.8

56.4

Selling, general & administration

(882

)

(813

)

(8

)

(5

)

Research & development

(245

)

(222

)

(10

)

(8

)

Other income

11

149

(93

)

(92

)

Other expense

(117

)

(29

)

nm

nm

Operating income

292

468

(38

)

(42

)

Operating margin (%)

10.9

19.1

Core results (non-IFRS measure)(1)

Core gross profit

1,691

1,550

9

5

Core gross margin (%)

63.0

63.2

Core operating income

569

511

11

6

Core operating margin (%)

21.2

20.8

Non-operating income & expense

Three months ended March 31

Change %

($ millions unless indicated otherwise)

2026

2025

$

cc(1)
(non-IFRS
measure)

Operating income

292

468

(38

)

(42

)

Interest expense

(52

)

(49

)

(6

)

(4

)

Other financial income & expense

2

9

(78

)

(83

)

Share of (loss) from associated companies

(2

)

(14

)

86

85

Income before taxes

240

414

(42

)

(48

)

Taxes

(51

)

(64

)

20

28

Net income

189

350

(46

)

(51

)

Net income attributable to:

Shareholders of Alcon Inc.

189

350

(46

)

(51

)

Non-controlling interests

—

—

—

—

Basic earnings per share ($)(2)

0.39

0.71

(45

)

(50

)

Diluted earnings per share ($)(2)

0.39

0.70

(44

)

(50

)

Core results (non-IFRS measure)(1)

Core taxes

(102

)

(97

)

(5

)

—

Core net income

415

365

14

8

Core net income attributable to:

Shareholders of Alcon Inc.

415

365

14

8

Non-controlling interests

—

—

—

—

Core basic earnings per share ($)(2)

0.85

0.74

15

10

Core diluted earnings per share ($)(2)

0.85

0.73

16

10

Reconciliation of IFRS results to core results (non-IFRS measure)

Three months ended March 31, 2026

($ millions except earnings per share)

IFRS
results

Amortization
of certain
intangible
assets(1)

Impairments(2)

Acquisition and
integration
related items(4)

Efficiency
measures(5)

Other
items(6)

Core results
(non-IFRS
measure)

Gross profit

1,525

127

38

1

—

—

1,691

Operating income

292

129

38

21

88

1

569

Income before taxes

240

129

38

21

88

1

517

Taxes(7)

(51

)

(23

)

(6

)

(4

)

(17

)

(1

)

(102

)

Net income

189

106

32

17

71

—

415

Net income attributable to:

Shareholders of Alcon Inc.

189

106

32

17

71

—

415

Non-controlling interests

—

—

—

—

—

—

—

Basic earnings per share ($)(8)

0.39

0.85

Diluted earnings per share ($)(8)

0.39

0.85

Basic - weighted average shares outstanding (millions)(8)

487.2

487.2

Diluted - weighted average shares outstanding (millions)(8)

490.2

490.2

Three months ended March 31, 2025

($ millions except earnings per share)

IFRS
results

Amortization of
certain intangible
assets(1)

Gains on
investments in
associated
companies(3)

Acquisition and
integration
related items(4)

Other
items(6)

Core results
(non-IFRS
measure)

Gross profit

1,383

167

—

—

—

1,550

Operating income

468

172

(142

)

13

—

511

Income before taxes

414

172

(142

)

13

5

462

Taxes(7)

(64

)

(30

)

—

(3

)

—

(97

)

Net income

350

142

(142

)

10

5

365

Net income attributable to:

Shareholders of Alcon Inc.

350

142

(142

)

10

5

365

Non-controlling interests

—

—

—

—

—

—

Basic earnings per share ($)(8)

0.71

0.74

Diluted earnings per share ($)(8)

0.70

0.73

Basic - weighted average shares outstanding (millions)(8)

495.1

495.1

Diluted - weighted average shares outstanding (millions)(8)

498.0

498.0

Explanatory footnotes to IFRS to core reconciliation tables

(1)

Includes amortization for all intangible assets other than software.

(2)

Includes impairment charges related to intangible assets.

(3)

For the three months ended March 31, 2025, includes gains on fair value remeasurements of investments in associated companies.

(4)

For the three months ended March 31, 2026, Gross profit includes the amortization of inventory fair value adjustments related to an acquisition. Operating income also includes $20 million of direct acquisition costs. Acquisition costs include third party professional services for legal fees and other transaction related costs.

For the three months ended March 31, 2025, Operating income includes $7 million of direct acquisition costs and $6 million of integration related costs related to acquisitions. Acquisition costs include third party professional services for banker, legal, accounting and due diligence fees. Integration related costs include severance of $3 million, accelerated equity-based compensation expense of $2 million and third party professional services of $1 million.

(5)

For the three months ended March 31, 2026, includes restructuring costs, third party consulting fees and other direct costs related to efficiency initiatives. These efficiency measures were announced in February 2026 and implementation is expected to be completed this year.

(6)

For the three months ended March 31, 2026, Operating income primarily includes the amortization of option rights.

For the three months ended March 31, 2025, Income before taxes includes core adjustments recognized for Aurion in Share of (loss) from associated companies. The expenses were incurred upon change in control from Alcon's acquisition of a majority interest in Aurion and include accelerated equity-based compensation expense of $2 million, third party professional services of $2 million for legal and accounting fees and third party bank fees of $1 million.

(7)

For the three months ended March 31, 2026, total tax adjustments of $51 million include tax associated with operating income core adjustments and discrete tax items. Tax associated with operating income core adjustments of $277 million totaled $50 million with an average tax rate of 18.1%. Core tax adjustments for discrete tax items totaled $1 million.

For the three months ended March 31, 2025, operating income core adjustments totaled $43 million. Excluding the non-taxable gain of $136 million on fair value remeasurement of Alcon's investment in Aurion, the core adjustments totaled $179 million. The associated tax effect amounted to $33 million with an average tax rate of 18.4%.

(8)

Core basic earnings per share is calculated using core net income attributable to shareholders of Alcon Inc. and the weighted-average shares of common stock outstanding during the period. Core diluted earnings per share also contemplate dilutive shares associated with unvested equity-based awards as described in Note 5 to the Condensed Consolidated Interim Financial Statements.

EBITDA (non-IFRS measure)

Three months ended March 31

($ millions)

2026

2025

Net income

189

350

Taxes

51

64

Depreciation of property, plant & equipment

108

98

Depreciation of right-of-use assets

24

21

Amortization of intangible assets

152

191

Impairments of property, plant & equipment and intangible assets

38

—

Interest expense

52

49

Other financial income & expense

(2

)

(9

)

EBITDA

612

764

Cash flow and net (debt)/liquidity (non-IFRS measure)

Three months ended March 31

($ millions)

2026

2025

Net cash flows from operating activities

418

384

Net cash flows used in investing activities

(218

)

(578

)

Net cash flows used in financing activities

(133

)

(96

)

Effect of exchange rate changes on cash and cash equivalents

(16

)

26

Net change in cash and cash equivalents

51

(264

)

Change in derivative financial instrument assets

13

(7

)

Change in time deposits with original maturity greater than three months

1

(153

)

Change in current and non-current financial debts

3

(60

)

Change in net (debt)

68

(484

)

Net (debt) at January 1

(3,125

)

(2,802

)

Net (debt) at March 31

(3,057

)

(3,286

)

Net (debt)/liquidity (non-IFRS measure)

($ millions)

At March 31, 2026

  At December 31, 2025

  Current financial debt

(577

)

(575

)

Non-current financial debt

(4,157

)

(4,162

)

Total financial debt

(4,734

)

(4,737

)

    Less liquidity:

    Cash and cash equivalents

1,578

1,527

Time deposits with original maturity greater than three months

81

80

Derivative financial instruments

18

5

Total liquidity

1,677

1,612

Net (debt)

(3,057

)

(3,125

)

Free cash flow (non-IFRS measure)

The following is a summary of free cash flow for the three months ended March 31, 2026 and 2025, together with a reconciliation to net cash flows from operating activities, the most directly comparable IFRS measure:

Three months ended March 31

($ millions)

2026

2025

Net cash flows from operating activities

418

384

Purchase of property, plant & equipment

(139

)

(106

)

Free cash flow

279

278

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Connect with us on

Facebook

LinkedIn

More News From Alcon Inc. Swiss

Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Alcon (ALC - Free Report) Headquartered in Geneva, Switzerland Alcon Inc. (ALC - Free Report) researches, develops, manufactures, distributes, and sells a full suite of eye care products. Founded in 1945, Alcon was first acquired by a Swiss subsidiary of  Nestlé S.A. and began operating as a wholly owned subsidiary of Nestlé until 2002. From Mar 20, 2002 until its 2011-merger into Novartis, Alcon was publicly listed and traded on the NYSE. In 2011, Novartis completed the acquisition of 100% stake in Alcon.

ALC is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 18.85; value investors should take notice.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.18 to $3.47 per share. ALC boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ALC should be on investors' short list.

Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges on refill rates, payer coverage, and patient persistence. ALC's robust commercial footprint and strong balance sheet support ongoing R&D, M&A, dividends, and buybacks, mitigating financing risks.